According to an outside spokesperson for Power3, the company will begin clinical testing at three undisclosed US sites, and that it would likely be able to announce the exact timing of the trials in a few weeks.
The test uses proteomics techniques such as electrophoresis image analysis and automated mass spectrometry to analyze nipple aspirate, or breast ductal fluid for specific groups of breast cancer proteins. The fluid is collected via a non-invasive modified breast pump procedure.
Power3 said that the test has the potential to detect breast cancer years earlier than current methods. The company also said it has completed proof-of-concept studies and secured the intellectual property for the test.
In May, Power3 acquired proteomics start-up ProteEx, which had been developing the test in collaboration with the M.D. Anderson Cancer Center.